ArticleBlood neoplasia2025
Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compared with data from clinical trials, US population-level data show decreased effectiveness of hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS). We sought to identify factors associated with patterns of HMA use. In this retrospective cohort study, we identified 49 514 individuals aged ≥65 years with incident MDS during the years 2012 to 2013 using the 2011 to 2014 Medicare claims data set. We collected data on demographics, clinical characteristics, disease severity, and area-level socioeconomic measures. Multivariable logistic regression analysis was used to evaluate factors associated with receipt of HMA and duration of HMA therapy. A total of 7935 patients (16.1%) received HMAs. In adjusted analyses, the oldest age cohort (patients aged ≥85 years) had lower odds of receiving HMAs than their younger counterparts (aged 65-74 years; adjusted odds ratio [aOR], 0.41; 95% confidence interval [CI], 0.38-0.44). Females and Black patients had significantly lower odds than males and White patients to receive HMA (aOR, 0.81 [95% CI, 0.77-0.86] for females; aOR, 0.70 [95% CI, 0.62-0.8] for Blacks patients). In HMA recipients, factors associated with lower odds of receiving ≥4 cycles of HMAs included patients treated with decitabine (aOR, 0.7; 95% CI, 0.62-0.78), having 2 to 3 cytopenias (aOR, 0.69; 95% CI, 0.61-0.78), being nursing home residents (aOR, 0.64; 95% CI, 0.46-0.90), and having high frailty (aOR, 0.50; 95% CI, 0.34-0.75). We identified age-, sex-, and race-related disparities in receipt of HMAs, favoring younger, White males. The duration of therapy in HMA-treated patients in routine clinical practice showed wide divergence from recommended clinical guidelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.